Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment
Hematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant hemopathies, but highlights the limitations of long-term results due to the high toxicity of the procedure and the development of Graft versus Host Disease (GVHD). Conventional treatments for GVHD have limited success rates, and some patients may be refractory to ruxolitinib, a second-line treatment option. As a result, there is a need to explore alternative immuno-modulatory therapies, such as the use of Wharton's jelly mesenchymal stem cells (WJ-MSCs).

The research question aims to investigate the safety and potential benefits of sequentially infusing thawed or expanding allogeneic WJ-MSCs in the treatment of acute GVHD refractory to second-line treatment in patients from the Colombian population. This pilot clinical study is being conducted to address the unmet need for patients who develop GVHD resistant to ruxolitinib.
- EligibilityCriteria: Inclusion criteria:  Aged between 18 and 65 years. With a diagnosis of malignant hemopathies, who have undergone allogeneic HSCT and who are diagnosed with acute GVHD refractory to second-line treatment. Patients who have received bone marrow and/or peripheral blood as a source of cells. Patients who have received cells from a family or unrelated donor Myeloablative or non-myeloablative conditioning method. Adequate cardiac function without evidence of uncontrolled hypertension, congestive heart failure, angor pectoris, or acute myocardial infarction in the 6 months prior to the process. Adequate lung function without evidence of severe obstructive or restrictive lung disease. Informed consent signed by the patient.  Exclusion Criteria:  Patients from the Transplant Unit of the FOSCAL. Patients with a diagnosis of hemopathy that has not been controlled by the transplant or is progressing at the time of treatment. Bacterial, viral, or fungal infection that is not being controlled with adequate treatment. Cardiac and/or pulmonary function in uncontrolled altered conditions. According to medical criteria, patients who are not in an adequate situation to tolerate the treatment. Pregnant women or women at risk of pregnancy due to inadequate contraceptive measures. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult